Tag: MCIG

Blue Horseshoe Stocks: NEPT Review & More

Neptune Technology & Bioresources, Inc. NEPT

To start off the new calendar year on a high note, we’d like to track back to a stock we placed on our radars on the morning of November 28th, and recap the solid bullish performance that followed.

NEPT has been in a general uptrend ever since our alert, and is showing a strong sign that it may continue. Subsequent to our initial report, we observed a low of 1.30 in the stock, and as of the new high achieved to close out last week at 2.44. it marked an increase of 88%

We’ll continue to observe this stock, and will want to see it maintain support at or above the 2.20-area on any pullbacks.

INSYS Therapeutics, Inc. INSY

We formulated an options trading idea for the INSY 01/19 $8 and $9 Calls on Wednesday morning, and on Friday. mentioned that despite only moderate gains in the previous session, that we’d still be looking for our opportunity to come along.

Friday’s session facilitated some solid moves in our highlighted contracts, and current conditions suggest we could see an extension to the already significant gains that were there for the taking to close out the 2017 trading year.

The $8 Calls ran from .90-2.27, for a gain of 152%, while the $9’s traded up from .60 to 1.51, which works out to a 151% move.

INSY has traded as high as 10.25 in premarket trading today, and we will look to roll up our strike price to the $10-level if the stock holds above this morning’s premarket low of  9.75 once the session gets rolling.

Extended Watchlist:
TEUM, WATT, SBGL, SSC, MCIG, AGTK, GLDFF, VPER

Blue Horseshoe Stocks: Cannabis Sector Heating Up Again

Cannabis Comments

We got head-faked a little bit in terms of the cannabis sector in the past year or so. Leading up to last fall, anything even remotely tied to marijuana was going through the roof, with seemingly no end in sight. Then a regime change in Washington led to the appointment of self-avowed cannabis hater Jeff Sessions to the head of the DOJ. That led to a considerable cooling of what was previously the hottest market sector.

That being said, it has been business as usual for companies operating in the space in places that have taken the step of ending prohibition. Growth is happening all around, and the investment community has taken notice. The cannabis sector is showing signs of heating up once again, so we want to return to some of the plays we’ve covered in the past and highlight a few that could stand to see some good moves in the days and weeks ahead.

Dewmar International, Inc. DEWM – We just signaled our interest in DEWM in Friday morning’s premarket report, and the stock made a solid two-session swing. From Friday’s low of .0108 to .0163 yesterday, marking a move of 51% We’ll want to continue to track its movements,particularly after this morning’s news.

DEWM announced today that it filed a provisional patent with the US Patent and Trademark Office for the treatment of lung cancer with cannabinoids, so that’s going to be another interesting storyline to follow with respect to DEWM.
_____

Also going on our refreshed cannabis watchlist of previously tracked stocks will be PNTV, POTN, MCIG, MCOA, and TRTC.

Netflix, Inc. NFLX – Options

We’re always looking for a good post-earnings options play and we may have one with NFLX this morning. Up 10% in premarket trading on a solid beat, we’re going to be looking for a potential dip-and-rip scenario that could lead to some hefty intraday moves. Our targets are going to be the NFLX Weekly $172.50-180 Calls.

Extended Watchlist:
CAPR, MBRX, MDGS, NVAX, OPK OPCO, TTOO, RAD

Blue Horseshoe Stocks: News Plays & Special Reminder

Aeterna Zentaris, Inc. AEZS

AEZS is gapping up this morning on the heels of some news. It’s been quite a few months since we last mentioned this stock. That was back in the fall, and we subsequently witnessed quite a surge from the stock after that.

Since then, so far in 2017 the stock has come down to record new annual lows, and recently has been making incremental increases off of that bottom. In light of today’s news, described below, we think it’s a good time to put AEZS back on a more intensive watch.

The company announced this morning, following a comprehensive review Phase 3 clinical data on Macrilen™ for the evaluation of growth hormone deficiency, that Macrilen™ demonstrated performance supportive of achieving registration with the FDA. The FDA has agreed to consider the Company’s conclusions during a Type A meeting, which is currently being scheduled. (>>View PR)

Zosano Pharma Corp. ZSAN

Speaking of fresh news plays, we also want to highlight the announcement coming from ZSAN this morning that presently has the stock gapping up in the premarket to the tune of 50%

This morning ZSAN reported that in its ZOTRIP pivotal efficacy study, the company’s M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints. It certainly explains the premarket hoopla, and warrants our observation as we kick off a new trading week.

The chart also has some attractive features which we’ve pointed out on the snapshot below:

**SPECIAL REMINDER**

To wrap things up this morning, we want to leave our readers with a quick heads up on a big Tuesday coming up. We’ve got a special report coming out tomorrow prior to the opening bell. It could represent quite an opportunity, so tomorrow is definitely not the day to miss out on our premarket report!

Be sure to stay locked onto your email inboxes or BlueHorseshoeStocks.com tomorrow between 9:00 to 9:15AM, and lean on those refresh buttons!

Extended Watchlist:
MCIG, MYHI, ADVT, MJTK, QSIM, NK